Journal of Antimicrobial Chemotherapy, Vol 39, 53-61, Copyright © 1997 by The British Society for Antimicrobial Chemotherapy
IM Gould and K Milne
Six isolates each of Enterococcus faecium, Staphylococcus aureus,
Staphylococcus epidermidis, Streptococcus pyogenes, Stenotrophomonas
maltophilia, Pseudomonas aeruginosa, Citrobacter spp., Serratia spp.,
Acinetobacter spp. and Enterobacter spp. (total 60 strains) were studied
against the combination of piperacillin/tazobactam plus gentamicin or
ciprofloxacin at physiological concentrations by the microtitre
chequerboard method incorporating simultaneous time-kill curves. Tazobactam
was fixed at 4 mg/L. Gentamicin plus piperacillin/tazobactam was a synergic
combination against 28 strains at 2 h, 51 at 5 h and 54 at 24 h as assessed
by time-kill curves and synergic or additive (FBC index < or = 1)
against all 60 strains at 24 h by chequerboards. The corresponding figures
for ciprofloxacin plus piperacillin/tazobactam were seven, 26, 52 and 58
respectively. Antagonism (FBC index > or = 4) was demonstrated for one
strain to each combination at 24 h. There were no significant differences
between FIC indices and FBC indices for each antibiotic combination.
Gentamicin plus piperacillin/tazobactam gave > or = 3 log kill for 47
strains by 2 h, 56 by 5 h and 59 by 24 h. Ciprofloxacin plus
piperacillin/tazobactam gave > or = 3 log kill for 22 strains by 2 h, 36
by 5 h and 56 by 24 h. In conclusion both antibiotic combinations at
physiological concentrations were synergic or additive at 24 h for the
majority of strains tested although notably gentamicin plus
piperacillin/tazobactam gave faster kill. Antagonism was rarely seen. Both
combinations are likely to prove beneficial for treatment of serious
infections.
JOURNAL ARTICLE
In-vitro pharmacodynamic studies of piperacillin/tazobactam with gentamicin and ciprofloxacin
Department of Medical Microbiology, Aberdeen Royal Hospital NHS Trust, Aberdeen Royal Infirmary, UK.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. E. N. Milne and I. M. Gould Combination testing of multidrug-resistant cystic fibrosis isolates of Pseudomonas aeruginosa: use of a new parameter, the susceptible breakpoint index J. Antimicrob. Chemother., October 27, 2009; (2009) dkp384v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. P. Allen, R. Cha, and M. J. Rybak In Vitro Activities of Quinupristin-Dalfopristin and Cefepime, Alone and in Combination with Various Antimicrobials, against Multidrug-Resistant Staphylococci and Enterococci in an In Vitro Pharmacodynamic Model Antimicrob. Agents Chemother., August 1, 2002; 46(8): 2606 - 2612. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. H. Drew, J. R. Perfect, L. Srinath, E. Kurkimilis, M. Dowzicky, G. H. Talbot, and for the Synercid Emergency-Use Study Group Treatment of methicillin-resistant Staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy J. Antimicrob. Chemother., November 1, 2000; 46(5): 775 - 784. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. C. Fuchs, A. L. Barry, and S. D. Brown Bactericidal Activity of Quinupristin-Dalfopristin against Staphylococcus aureus: Clindamycin Susceptibility as a Surrogate Indicator Antimicrob. Agents Chemother., October 1, 2000; 44(10): 2880 - 2882. [Abstract] [Full Text]
|
|
|
|
|
|
S. Gander and R. Finch The effects of exposure at constant (1 h) or exponentially decreasing concentrations of quinupristin/dalfopristin on biofilms of Gram-positive bacteria J. Antimicrob. Chemother., July 1, 2000; 46(1): 61 - 67. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F.-J. Schmitz, J. Verhoef, A. C. Fluit, and The Sentry Participants Group Prevalence of resistance to MLS antibiotics in 20 European university hospitals participating in the European SENTRY surveillance programme J. Antimicrob. Chemother., June 1, 1999; 43(6): 783 - 792. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Mayer and E. Nagy Investigation of the synergic effects of aminoglycoside- fluoroquinolone and third-generation cephalosporin combinations against clinical isolates of Pseudomonas spp. J. Antimicrob. Chemother., May 1, 1999; 43(5): 651 - 657. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Denton and K. G. Kerr Microbiological and Clinical Aspects of Infection Associated with Stenotrophomonas maltophilia Clin. Microbiol. Rev., January 1, 1998; 11(1): 57 - 80. [Abstract] [Full Text] [PDF]
|
|